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Aging sarcopenia and muscular dystrophy (MD) are two conditions characterized by lower
skeletal muscle quantity, lower muscle strength, and lower physical performance. Aging
is associated with a peculiar alteration in body composition called “sarcopenic obesity”
characterized by a decrease in lean body mass and increase in fat mass. To evaluate the
presence of sarcopenia and obesity in a cohort of adult patients with MD, we have used
the measurement techniques considered golden standard for sarcopenia that is for muscle
mass dual-energy X-ray absorptiometry (DXA), for muscle strength hand-held dynamom-
etry (HHD), and for physical performance gait speed. The study involved 14 adult patients
with different types of MD.We were able to demonstrate that all patients were sarcopenic
obese. We showed, in fact, that all were sarcopenic based on appendicular lean, fat and
bone free, mass index (ALMI). In addition, all resulted obese according to the percentage
of body fat determined by DXA in contrast to their body mass index ranging from under-
weight to obese. Skeletal muscle mass determined by DXA was markedly reduced in all
patients and correlated with residual muscle strength determined by HHD, and physical
performances determined by gait speed and respiratory function. Finally, we showed that
ALMI was the best linear explicator of muscle strength and physical function. Altogether,
our study suggests the relevance of a proper evaluation of body composition in MD and
we propose to use, both in research and practice, the measurement techniques that has
already been demonstrated effective in aging sarcopenia.
Keywords: muscular dystrophy, sarcopenia, sarcopenic obesity, body composition, muscle strength, physical
performance
INTRODUCTION
Muscular dystrophies (MDs) are a clinically and genetically hetero-
geneous group of inherited diseases characterized by progressive
muscle wasting and weakness (Emery, 2002). In the dystrophic
muscle, there is a progressive loss of muscle fibers that are substi-
tuted by fat and connective tissue. The dystrophic muscle weakness
reflects the loss of muscle tissue and compromises physical perfor-
mance. In summary, MD can specifically be defined as a condition
characterized by lower skeletal muscle quantity, lower muscle
strength, and lower physical performance. The other condition
that combines these three characteristics is sarcopenia.
Sarcopenia is defined according to European consensus group
(Cruz-Jentoft et al., 2010) as a condition that involves a loss
of muscle mass and declining strength and/or physical perfor-
mance. In particular, “severe sarcopenia” is the stage identified
when all three criteria of the definition are met (low muscle
mass, low muscle strength, and low physical performance) (Cruz-
Jentoft et al., 2010). With aging, skeletal muscle atrophy in human
beings appears to be inevitable. A gradual loss of muscle fibers
begins at approximately 50 years of age and continues such that
by 80 years of age, approximately 50% of the fibers are lost from
the limb muscles that have been studied (Faulkner et al., 2007).
Although primarily a disease of the elderly, sarcopenia can be
observed at any age resulting associated with conditions like
disuse, malnutrition, and neuromuscular diseases (Muscaritoli
et al., 2010).
Body composition changes with aging. Cross-sectional and lon-
gitudinal data have shown that aging is associated with a peculiar
alteration in body composition – a decrease in lean body mass
and increase in fat mass (FM). Baumgartner et al. (2004) have
proposed criteria for this new condition that combines sarcopenia
and obesity, which has been called sarcopenic/obesity (Baumgart-
ner et al., 2004). High body mass index (BMI), low muscle mass,
and the combination of excess FM with low muscle mass have
been associated with increased risk for physical disability in older
adults (Fielding et al., 2011). It is, therefore, recognized that sar-
copenic/obesity has an important impact on physical capacity in
older individuals as the prevalence of this condition is<10% of the
elderly population (Baumgartner et al., 2004; Batsis et al., 2013),
whereas the prevalence of sarcopenia is 13–36% and circa 30% of
older Americans are obese (Jankowski et al., 2008).
The aim of this study was to evaluate the presence and sever-
ity of sarcopenia and of sarcopenic obesity in a cohort of adult
patients with MD. In order to conduct a valid and reliable diagnosis
of these conditions in patients with MD, we have measured muscle
mass, muscle strength, and physical performance. The measure-
ment techniques were the ones suggested by the European Working
Group, recognized useful both in research and practice that is for
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muscle mass dual-energy X-ray absorptiometry (DXA), for mus-
cle strength hand-held dynamometry (HHD), and for physical
performance gait speed (Mijnarends et al., 2013).
MATERIALS AND METHODS
PATIENTS
We included in the study, adult patients with a clinical and molecu-
lar diagnosis of MD and clinical and body composition evaluations
performed within 1 month and with the same equipment. Data
of 14 adult patients (7 were women) with a clinical/laboratory
phenotype compatible with the diagnosis of MD were collected.
The mean age of women was 35.6 (range 19–56) years and of
men 29.5 (range 18–64) years; this difference was not significant
(p= 0.47). All the patients had a definite molecular diagnosis.
There were six patients with Bethlem myopathy (BM) and one
with Ullrich congenital muscular dystrophy (UCMD) with recog-
nition of a pathogenetic mutation/s in one of the three COL6
genes (Pepe et al., 1999; Lucioli et al., 2005; Merlini et al., 2008b;
Gualandi et al., 2009, 2011; Martoni et al., 2009; Sabatelli et al.,
2011, 2012). Two patients had a rigid spine syndrome due to a
mutation of the FHL1 gene. One patient had a limb girdle MD
type 2D (LGMD2D) due to a homozygous mutation in the alpha-
sarcoglycan gene. Three patients had a Duchenne MD (DMD) and
one a Becker MD (BMD) with mutations in the DMD gene. Three
patients were non-ambulatory: the UCMD patient was never able
to walk and was on nocturnal non-invasive ventilation, the patient
with LGMD2D and one with rigid spine lost ambulation at 15
and 21 years of age, respectively. The study protocol was approved
for patients with MD by the institutional ethical committee in
1994 and specifically for patients with COL6 related myopathies
in 2011 (ClinicalTrials.gov identifier: NCT01438788). All subjects
were fully informed and gave their written informed consent.
BODY COMPOSITION
Body composition was obtained by DXA (Hologic 4500 W; soft-
ware version 11.2; Hologic, Inc., Waltham, MA). According to
the tree-compartment model of body composition, the Hologic
software provided regional and whole body estimation of lean
mass (LM), FM, and bone mineral content (BMC). BMC and
LM were added to obtain fat-free mass (FFM). Appendicular lean
mass (ALM) was the sum of bone-free and fat-free tissue mass
in the arms and legs. Body mass, FM, LM, FFM, and ALM were
normalized to height2 to control for skeletal size. ALM/height2,
appendicular lean mass index (ALMI), was considered the sar-
copenia index. ALMI two standard deviations (Baumgartner et al.,
1998) or more (Tanko et al., 2002; Newman et al., 2003) lower
than a mean derived from young male and female reference
groups was defined as the gender-specific cut point for sarcope-
nia (Baumgartner et al., 1998; Tanko et al., 2002; Newman et al.,
2003). BMI, an index of obesity, was derived from body mass
measured by DXA to the nearest gram and height measured to
the nearest 0.1 cm. We used BMI to categorized participants as
obese (BMI≥ 30), overweight (25≤BMI< 30), normal weight
(18.5<BMI< 25), or underweight (≤18.5) (WHO, 2000). Sar-
copenic obesity was defined according to Baumgartner et al. (2004)
as ALMI< 7.26 kg/m2 in men and 5.45 kg/m2 in women and per-
centage body fat greater than 28% in men and 40% in women
(Baumgartner et al., 2004).
MUSCLE STRENGTH AND PHYSICAL PERFORMANCES
Maximal isometric strength was assessed using a hand-held
dynamometer (Type CT 3001, Citec, C.I.T. Technics BV, Gronin-
gen, The Netherlands) (van der Ploeg et al., 1991). Two muscle
groups were examined bilaterally: handgrip (HG) and knee exten-
sor (KE) (Merlini et al., 2002, 2003, 2004). The maximum force
from three attempts was used in analysis. Patients were considered
to have low muscle strength if HG strength was<20 kg in women
and <30 kg in men (Bohannon et al., 2006; Cruz-Jentoft et al.,
2010). This is also the diagnostic threshold in handgrip strength
that best discriminates subjects with mobility limitations to be
used in clinical practice (Fried et al., 2001; Lauretani et al., 2003).
A ratio of maximal muscular strength of knee extensors to body
weight was calculated by dividing the muscular strength (N) by
body weight (kg). In older adults (81–89 years), muscular strength
thresholds to perform activities of daily living (ADL) indepen-
dently were 2.8 N/kg for knee extensors (Hasegawa et al., 2008).
Ploutz-Snyder et al. (2002) have found similar figures: ambula-
tory tasks (chair rise, gait speed, and stair ascent and descent)
were compromised in individuals with a ratio of isometric leg
extension peak torque to body weight (STR/WT) <3.0 N m/kg
(Ploutz-Snyder et al., 2002).
Forced vital capacity (FVC) was determined with an electronic
spirometer, and percent-predicted values were calculated based
on normal published values. A value between 50 and 70% was
considered moderately reduced; a value less than 50% was con-
sidered severely reduced (van der Kooi et al., 2006). Timed test
included the time to walk 10 m. Patients were considered to have
a low mobility based on the walking speed threshold of 1.22 m/s
proposed by Langlois et al. (1997), evaluating the ability to cross
the street in the time typically allotted at signalized intersections
(Langlois et al., 1997).
STATISTICAL ANALYSIS
In order to determine the separate relative contributions of the var-
ious indices to the strength variables, we used the linear regression
models. Due to the limited sample size, we chose to estimate the
linear regression model without intercept, y i= bx i+ e i, via ordi-
nary least squares. Each b coefficient is the slope of the regression
line and represents the increment/decrement of the dependent
variable for a unit increment of each explanatory variable. Lin-
ear correlation coefficients have, therefore, been computed for
various couples of variables with the aim of choosing the vari-
ables for simple linear models without intercept. High values of
the linear correlation coefficients helped in the choice of iden-
tifying the body mass and muscularity as explanatory variables
to the dependent variables muscle strength, gait speed, and pul-
monary function. The strength of each simple linear relationship
was investigated via the adjusted R2, which represents a well-
known goodness of fit measure. Measurable variables are pre-
sented as mean (x)± SD and their range of variation is presented
in parentheses.
RESULTS
BODY COMPOSITION
Six participants were normal weight, four overweight, three under-
weight, and one obese based on BMI (Table 1). All were sarcopenic
based on ALMI, which was well below of the cut off for the
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Table 1 | Body mass, adiposity, and muscularity.
Women (n=7) Men (n=7) p-value
Total mass (kg) 60.90±13.09
(45.47–76.38)
61.05±16.80
(40.01–79.63)
0.99
BMI (kg/m2) 22.41±4.61
(16.10–29.20)
23.99±4.79
(17.40–31.70)
0.54
Total fat (%) 50.66±6.02
(41.30–58.50)
42.93±8.61
(29.70–58.80)
0.08
FMI (kg/m2) 11.54±3.58
(7.10–17.10)
10.53±4.04
(5.70–18.60)
0.63
FFMI (kg/m2) 10.86±1.23
(9.00–12.70)
13.30±2.01
(9.60–15.40)
0.02
LMI (kg/m2) 10.20±1.19
(8.50–12.10)
12.76±1.87
(9.40–14.70)
0.01
ALMI (kg/m2) 3.84±0.69
(3.14–4.78)
4.82±0.81
(3.67–5.55)
0.03
Kg, kilogram; BMI, body mass index; m2, square meter; FMI, fat mass index;
FFMI, fat-free mass index; LMI, lean mass index; ALMI, appendicular lean mass
index.
Summaries of individual data grouped according to sex. p-Value of the two sample
t-test for the mean.
sarcopenia index of 7.26 kg/m2 for men and 5.45 for women,
and all were sarcopenic obese based on ALMI and % FM that
was greater than 28% in men and 40% in women. In addition,
ALMI was significantly different (p≈ 0.00) between walkers and
non-walkers (4.6± 0.8 vs. 3.4± 0.3). FFMI was well below the
fifth percentile for all the patients as compared to the normal
age-related Italian population and also to the 70–80–year olds
(17 kg/m2 in men and 13.4 kg/m2 in women) (Coin et al., 2008).
Gender differences in body composition were significant for the
indices of muscularity (FFMI, LMI, and ALMI) but not for total
mass, BMI, and FMI.
MUSCLE STRENGTH AND PHYSICAL FUNCTION
Muscle strength was markedly reduced comparing with the nor-
mative values (van der Ploeg et al., 1991; Beenakker et al., 2001)
(Table 2). Knee extension strength (KES) with a mean value of
60 N (range 15–132 N) was very weak comparing with healthy
subjects in which it exceeded in both genders 250 N (van der Ploeg
et al., 1991; Beenakker et al., 2001). Non-walkers had a signifi-
cant lower (p≈ 0.00) KES mean value as compared with walkers
(22.5 N vs. 69.2 N). HGS was also very weak, and in all well below
theT -score value less than−2 (20 kg in women and 30 kg in men).
Again, there was a significant difference (p= 0.011) between mean
HGS of non-walkers and walkers (2.9 kg vs. 13.0 kg), confirm-
ing that HGS is a good indicator of global muscle strength. The
ratio between KES and body weight was in all well below (range
0.3–1.7 N/kg) the threshold (2.8 N/kg) in which performance on
ambulatory tasks is compromised. Walking speed was below the
threshold of 1.22 m/s, indicating a low mobility, in 10 patients
(range 0–1, 11 m/s), and above it in 4 (range 1.25–1.72 m/s).
% FVC was moderately (<70%) reduced in four, and severely
Table 2 | Muscle strength and measured physical function.
Women (n=7) Men (n=7) p-value
HGS (kg) 9.69±5.98
(1.00–18.50)
11.91±6.35
(4.50–22.50)
0.51
KES (N) 62.86±41.22
(15.00–131.00)
56.29±40.67
(18.00–132.00)
0.77
KES/body
weight (N/kg)
1.00±0.57
(0.30–1.80)
0.90±0.57
(0.40–1.70)
0.75
Gait speed
(m/s)
1.01± 0.73
(0.00–1.72)
0.81±0.40
(0.00–1.25)
0.55
FVC (L) 1.74±0.97
(0.46–2.77)
3.06±0.62
(2.09–3.93)
0.01
% FVC 49.71±29.12
(13.00–90.00)
79.43±14.63
(53.00–90.00)
0.04
HGS, handgrip strength; kg, kilogram; KES, knee extension strength; N, Newton;
m, meter; s, second; FVC, forced vital capacity; L, liter.
Summaries of individual data grouped according to sex. p-value of the two sample
t-test for the equality of the means.
Table 3 | Linear correlation coefficients between muscle strength
(lines) and physical function (columns) variables.
Gait speed (m/s) FVC (L) % FVC
HGS (kg) 0.72 (0.00) 0.59 (0.03) 0.59 (0.03)
KES (N) 0.57 (0.03) 0.12 (0.68) 0.08 (0.77)
KES/body weight (N/kg) 0.55 (0.03) 0.05 (0.87) 0.11 (0.70)
HGS, handgrip strength; kg, kilogram; KES, knee extension strength; N, Newton;
m, meter; s, second; FVC, forced vital capacity; L, liter.
In parentheses, the p-value of the test for equality to zero of the correlation
coefficient.
reduced (<50%) in three patients (range 13–41%); non-walkers
had a significantly lower (p= 0.03) % FVC as compared with walk-
ers (39 vs. 72). Gender differences were significant only for FVC
and % FVC.
CORRELATION BETWEEN BODY COMPOSITION, MUSCLE STRENGTH,
AND PHYSICAL FUNCTION
Knee extension strength measures and gait speed showed moderate
correlation coefficient significantly different from zero (Table 3).
On the other hand, the coefficient between HGS and the phys-
ical function variables were all significant, showing a moderate
to strong correlation (Table 3). The linear correlation coefficients
between couples of possible explicative variables of muscularity
showed values oscillating between 0.01 and 0.58 in absolute value.
The indices of adiposity, total fat % and FMI, had non-significant
linear correlation coefficient with all the muscle strength and phys-
ical function variables (Table 4). On the contrary, the indices of
muscularity showed moderate positive values (0.40–0.58) when
associated with FFMI and ALMI (Table 4); moreover, the HGS,
FVC, and % FVC are significantly different from zero. The good-
ness of fit of the relationship between the predictor variables (BMI
and ALMI) and the dependent variables (HGS, KES, % FVC, gait
Frontiers in Aging Neuroscience www.frontiersin.org October 2014 | Volume 6 | Article 274 | 3
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Merlini et al. Sarcopenia in muscular dystrophy
Table 4 | Linear correlation coefficients between potential dependent
(lines) and explanatory (columns) variables.
Total fat % FMI FFMI ALMI
HGS (kg) −0.21 (0.47) 0.03 (0.91) 0.58 (0.03) 0.51 (0.06)
KES (N) 0.20 (0.48) 0.36 (0.21) 0.43 (0.12) 0.48 (0.08)
Gait speed (m/s) 0.08 (0.79) 0.28 (0.34) 0.43 (0.13) 0.40 (0.15)
FVC (L) −0.19 (0.51) 0.09 (0.75) 0.48 (0.08) 0.55 (0.04)
% FVC −0.31 (0.28) 0.01 (0.96) 0.55 (0.04) 0.54 (0.05)
HGS, handgrip strength; kg, kilogram; KES, knee extension strength; N, Newton;
m, meter; s, second; FVC, forced vital capacity; L, liter; FMI, fat mass index; FFMI,
fat-free mass index; ALMI, appendicular lean mass index.
In parentheses, the p-value of the test for equality to zero of the correlation
coefficient.
Table 5 | Linear models (y i = βx i +ei) of separate relative contribution
of body mass and muscularity to muscle strength and physical
function and the p-value of the test for equality to zero of the
adjusted coefficient of linear determination.
Dependent variables Predictor variables β R2 p-Value
HGS (Kg) BMI 0.46 0.78 0.00
ALMI 2.53 0.82 0.00
KES (N) BMI 2.62 0.75 0.00
ALMI 14.05 0.75 0.00
% FVC BMI 2.74 0.85 0.00
ALMI 14.97 0.89 0.00
Gait speed (m/s) BMI 0.04 0.75 0.00
ALMI 0.21 0.75 0.00
R2, adjusted coefficient of linear determination; HGS, handgrip strength; kg, kilo-
gram; KES, knee extension strength; N, Newton; FVC, forced vital capacity; m,
meter; s, second; BMI, body mass index; ALMI, appendicular lean mass index.
speed) was measured by the adjusted R2, which was always dif-
ferent from zero (Table 5). Its values are always highly significant
and, therefore, suggest a good approximation of the suggested
regression model.
DISCUSSION
This study shows that adult MD patients can be classified according
to the definition criteria of sarcopenia (Cruz-Jentoft et al., 2010).
Our patients in spite of varying degree of impairment of muscle
function, from mild to severe, all had “severe sarcopenia” that is
the combination of low muscle mass, low muscle strength, and
low physical performance (Cruz-Jentoft et al., 2010). The studied
patients were also defined“sarcopenic obese” having in addition to
a severe decrease in lean body mass an increase in FM (Baumgart-
ner et al., 2004; Stenholm et al., 2008). ALMI was markedly reduced
in all patients and correlated with the residual muscle strength in
the arms and legs, and with physical performances determined by
gait speed and FVC. In addition, ALMI and muscle strength were
significantly reduced in non-walkers as compared to walkers.
A similar alteration in body composition, that is, decrease in
lean body mass and increase in FM, was reported in patients with
different types of MD (Skalsky et al., 2008, 2009; Pruna et al.,
2011). Patients with facioscapulohumeral MD had higher fat tis-
sue mass and lower lean tissue mass, despite similar BMI than
controls (Skalsky et al., 2008). Patients with myotonic dystrophy
had lower regional FFM index and higher fat mass index than
controls (Pruna et al., 2011). However, in these studies, body
composition was compared with age-matched, able-bodies con-
trols, and not with the older adults impeding the recognition
of sarcopenia.
Body composition, assessed by DXA, has started to be included
in clinical trials as a primary or secondary endpoint in addition to
the evaluation of muscle strength and function (Kissel et al., 2001;
Merlini et al., 2008a; Vuillerot et al., 2014). A randomized, double-
blind, placebo-controlled trial of albuterol in facioscapulohumeral
dystrophy showed that although albuterol did not improve global
strength or function, it did increase muscle mass assessed by DXA
and improve some measures of strength (Kissel et al., 2001). The
influence of a 2-year steroid treatment on body composition mea-
sured by DXA was evaluated in 29 DMD boys (Vuillerot et al.,
2014). The 21 boys of the steroid group treatment improved signif-
icantly in body composition through a significant increase in lean
tissue mass. In the steroid-naive patients, there were no significant
increases in the lean tissue mass but deterioration in body com-
position was confirmed by a significant increase in the percentage
of body FM (Vuillerot et al., 2014).
Loss of muscle mass and increased intramuscular fibrosis char-
acterize both aging and MD. Research has shown that skele-
tal muscle wasting in aging and in muscular dystrophic share
some pathophysiological mechanisms, including mitochondrial
dysfunction (Irwin et al., 2003; Marzetti et al., 2013), increased
apoptosis (Marzetti and Leeuwenburgh, 2006; Merlini et al., 2008a;
Calvani et al., 2013), abnormal modulation of autophagy (Wohlge-
muth et al., 2010; Merlini et al., 2014), decline in satellite cells
(Thornell, 2011; Jiang et al., 2014), increased generation of reactive
oxygen species (Doria et al., 2012; Canton et al., 2014), and modifi-
cation of signaling and stress response pathways (Deldicque, 2013;
Marzetti et al., 2013; Canton et al., 2014). Therefore, a standard
evaluation of sarcopenia may be of benefit for both conditions:
aging and MD.
Altogether, this study shows that aging sarcopenia criteria can
be used in the evaluation of patients with MD providing relevant
information in terms of residual muscle mass,muscle strength,and
physical function, which may justify its broader implementation
in future research, clinical trials, and clinical practice.
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